

Datasheet: MCA6149

BATCH NUMBER 172985

Description:	HUMAN ANTI CD30 (BRENTUXIMAB BIOSIMILAR)
Specificity:	CD30
Other names:	TNFRSF8
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	cAC10
Isotype:	IgG1
Quantity:	0.2 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human
Product Form	Human IgG1 (kappa) antibody - liquid
Preparation	Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
Immunogen	Human CD30

**External Database
Links**

UniProt:

[P28908](#) [Related reagents](#)

Entrez Gene:

[943](#) TNFRSF8 [Related reagents](#)

Synonyms

CD30, D1S166E

Specificity

Human Anti-CD30 antibody, clone cAC10, is a research grade biosimilar of the chimeric monoclonal antibody drug brentuximab. This product is supplied in a research grade format, i.e. in PBS buffer with preservative, it is not manufactured or formulated in the same way as the therapeutic reference product. A preservative free version is available [on request](#).

This product is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic brentuximab antibody clone cAC10. This product is not coupled to the drug monomethyl auristatin E (MMAE).

Brentuximab vedotin (Adcetris) is an antibody drug conjugate that combines the anti-CD30 antibody (brentuximab) with the anti-mitotic agent MMAE (vedotin). It is approved for the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. The brentuximab antibody selectively targets tumor cells expressing the cell membrane protein CD30 and delivers the MMAE, which causes apoptosis by preventing cell cycle progression of the G2 to M phase through disruption of the cytosolic microtubule network, thereby preventing tumor growth and proliferation.

This product is NOT FOR THERAPEUTIC USE.

Purity

>98% by SDS PAGE

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee

12 months from date of despatch

Acknowledgements

This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.

**Health And Safety
Information**

Material Safety Datasheet documentation #10040 available at:
<https://www.bio-rad-antibodies.com/SDS/MCA6149>

Licensed Use

For *in vitro* research purposes and for commercial applications for the provision of *in vitro*

testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory

For research purposes only

Product inquiries: www.bio-rad-antibodies.com/technical-support

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M430195:240503'

Printed on 29 Jan 2026

© 2026 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)